<DOC>
	<DOCNO>NCT02876718</DOCNO>
	<brief_summary>The main objective study ass preference Non Valvular Atrial Fibrillation ( NVAF ) patient towards different option anticoagulation treatment . Patient preference anticoagulant treatment attribute ( convenience attribute ) , base Discrete Choice Experiment ( DCE ) interview elicit impact switch Vitamin K Antagonist ( VKA ) Xarelto® Atrial Fibrilation ( AF ) patient treatment satisfaction document , measure score difference Anti-Clot Treatment Scale ( ACTS ) score patient switch VKA Rivaroxaban .</brief_summary>
	<brief_title>Xarelto Evidence Real Life Patients ' Preference Satisfaction Study</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Female male patient ≥ 20 year age ( legal age limit Taiwan ) confirm diagnosis AF ( nonvalvular ) . Treatment VKA least 6 week . Decision initiate treatment Rivaroxaban make per investigator 's routine treatment practice . Written informed consent patient . Wilingness capability conduct two F2F interview . Contraindications use Rivaroxaban outline local product information . Concomitant treatment anticoagulant . Participation another study ( clinical intervention/observational ) within 3 month prior enrollment . Patients participate investigational program intervention outside routine clinical practice .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>